ArticleNature communications2026
Therapeutic modulation of the vitreoretinal fibrosis microenvironment in female mice using engineered macrophage-derived extracellular vesicles.
Yingjie Wang, Fuxiao Luan, Jiawei Zhao, Peilin Guo, Shuang Wang, Jinghui Wang, Dongfang Wang, Jing Hou, Xiaofeng Hu, Li Chen and 5 more
Abstract read
In one paragraphArticle in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Yingjie WangDepartment of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, PR China.
Fuxiao LuanDepartment of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, PR China.
Jiawei ZhaoDepartment of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, PR China.ORCID 0000-0003-3343-4676 Peilin GuoState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, PR China.
Shuang WangState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, PR China.ORCID 0000-0002-9189-602X Jinghui WangDepartment of Gastroenterology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.ORCID 0000-0002-5888-5708 Dongfang WangBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, PR China.ORCID 0000-0003-1368-028X Jing HouDepartment of Ophthalmology, Peking University People's Hospital, Beijing, PR China.
Xiaofeng HuDepartment of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, PR China.
Li ChenDepartment of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, PR China.
Xusheng CaoBeijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, PR China.
Guanghui MaState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, PR China. ghma@ipe.ac.cn.ORCID 0000-0001-9154-5556 Yong TaoDepartment of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, PR China. taoyong@mail.ccmu.edu.cn.ORCID 0000-0003-1443-2667 Ying TianDepartment of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, PR China. tianying@mail.ccmu.edu.cn.ORCID 0000-0003-3239-6567 Wei WeiState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, PR China. weiwei@ipe.ac.cn.ORCID 0000-0002-6244-3187 Funding
National Natural Science Foundation of China (National Science Foundation of China) T2225021
6 · The paper itselfAbstract
Vitreoretinal fibrosis, a hallmark of proliferative vitreoretinopathy (PVR) triggered by retinal detachment or ocular trauma, necessitates surgery. Through data mining of the vitreoretinal fibrosis microenvironment in PVR patients and mice, showing elevated transforming growth factor β1 (TGFβ1) and M2 macrophage enrichment, we designed and engineered extracellular vesicles that conferred anti-fibrotic efficacy against PVR. These M1 macrophage-derived vesicles (M1evs) were conjugated with anti-TGFβ1 antibodies (aT) via MMP-cleavable linkers (aT-cl-M1ev, termed ACE). Upon intravitreal injection in female PVR model mice, ACE selectively accumulates in lesions, where released antibodies neutralize TGFβ1 and M1evs inhibit M2 macrophage polarization, modulating the microenvironment to diminish vitreoretinal fibrosis. Further incorporating anti-platelet-derived growth factor receptor antibodies yields aTP-cl-M1ev (ACE
Indexed as
Cellular MicroenvironmentExtracellular VesiclesMacrophagesVitreoretinopathy, ProliferativeAnimalsDisease Models, AnimalFemaleFibrosisHumansIntravitreal InjectionsMiceMice, Inbred C57BLRetinaRetinal DetachmentTransforming Growth Factor beta1Vitreous BodyTransforming Growth Factor beta1
Identifiers
PMID42786151
PMCPMC13612821
What Socratic holds
Textmetadata
Read underepoch 390